DCGI gives nod for launching Brintellix in India

After receiving approval from Drug Controller General of India (DCGI), Lundbeck India Private Limited has announced the launch of Brintellix (Vortioxetine) in India for the treatment of patients suffering from Major Depressive Disorder (MDD).

Brintellix will be the first patented drug to be sold in India for depression.

According to a survey conducted by NIMHANS, an estimated 1 in 20 people in India suffers from depression. 

Maninder Singh Sahwney, Country Manager, Lundbeck India, said, "Brintellix is a multimodal antidepressant, which has been specifically designed to inhibit serotonin (happy hormone) reuptake and modulate the serotonergic activity of the neurons in the brain of affected patients. It is efficient in reducing the mood symptoms in adult patients with depression as measured by traditional scales and also demonstrate improvement of cognitive performance in adult patients with depression, as measured with neuropsychological tests."

"Depression is a complex disease that involves mood, physical and cognitive symptoms. We are pleased to be able to offer a new treatment option to the patients with depression which can address all the symptoms of depression, helping the patient to function better," he added.